Abstract:Objective To investigate the effect and safety of Mifepristone at different doses in the treatment of uterine fibroids.Methods A total of 100 patients with uterine fibroids treated in Family Planning Service Center of Xingning Maternal and Child Health Care Hospital of Guangdong Province from January 2016 to December 2017 were enrolled in the study and divided into control group and study group according to the random number table method,with 50 cases in each group.In the control group,25.00 mg/d Mifepristone was used,while in the study group,12.50 mg/d Mifepristone was adopted.The volume of uterine fibroids,serum hormone levels,clinical control rate,and incidence of adverse reactions before and after treatment were compared between two groups.Results Before treatment,there were no significant differences between uterine fibroid volume([45.30±12.55]cm3),follicle-stimulating hormone(FSH)([81.80±7.25]ug/L),luteinizing hormone(LH)([9.35±1.40]U/L),estradiol(E2)([276.65±21.65]pmol/L),progesterone(P)([7.80±1.45]nmol/L)in the study group and those respectively in the control group([45.35±12.50]cm3,[81.85±7.20]μg/L,[9.30±1.45]U/L,[276.60±21.60]pmol/L,[7.85±1.40]nmol/L)(P>0.05).After treatment,the uterine fibroid volume,FSH,LH,E2,and P in the study group were respectively(30.15±9.88)cm3,(6.33±1.29)μg/L,(8.08±1.21)U/L,(176.50±20.08)pmol/L,and(4.15±0.99)nmol/L,and in the control group they were respectively(30.03±9.25)cm3,(6.35±1.35)μg/L,(8.05±1.15)U/L,(175.90±21.55)pmol/L,and(4.10±0.95)nmol/L,which did not display statistical significance(P>0.05).The clinical control rate in the study group was 96.00%,which was higher than that in the control group accounting for 80.00%,and the difference was statistically significant(P<0.05).The incidence of adverse reactions in the study group(10.00%)was lower than that in the control group(38.00%),and the difference was statistically significant(P<0.05).Conclusion The use of 12.50 mg/d Mifepristone for uterine fibroids is effective and safe,which is worthy of promotion and application.
黄运福;石玲婷;李巧华;廖红苑. 不同剂量米非司酮治疗子宫肌瘤的效果及安全性[J]. 中国当代医药, 2018, 25(25): 144-146转150.
HUANG Yun-fu;SHI Ling-ting;LI Qiao-hua;LIAO Hong-yuan. Effect and safety of different doses of Mifepristone in the treatment of uterine fibroids. 中国当代医药, 2018, 25(25): 144-146转150.